Cart
sales@molnova.com
PSB-CB5
CAS No. 1627710-30-8
PSB-CB5( —— )
Catalog No. M34207 CAS No. 1627710-30-8
PSB-CB5 (GPR18-IN-32)2 is a GRP18 antagonist with anti-inflammatory activity and can be used to study obesity and metabolic disorders.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 123 | Get Quote |
|
| 5MG | 183 | Get Quote |
|
| 10MG | 310 | Get Quote |
|
| 25MG | 502 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NamePSB-CB5
-
NoteResearch use only, not for human use.
-
Brief DescriptionPSB-CB5 (GPR18-IN-32)2 is a GRP18 antagonist with anti-inflammatory activity and can be used to study obesity and metabolic disorders.
-
DescriptionPSB-CB5 is a potent and selective antagonist of GRP18. PSB-CB5 has the potential for the research of metabolic disease and obesity.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayCell Cycle/DNA Damage
-
TargetGPR
-
RecptorGPR
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1627710-30-8
-
Formula Weight384.88
-
Molecular FormulaC20H17ClN2O2S
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESO=C\1N2C(=N/C1=C\C3=CC(OCC4=CC=C(Cl)C=C4)=CC=C3)SCCC2
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Kotańska M, et al. Effects of GPR18 Ligands on Body Weight and Metabolic Parameters in a Female Rat Model of Excessive Eating. Pharmaceuticals (Basel). 2021;14(3):270.?
molnova catalog
related products
-
IBC 293
IBC 293 is selective for GPR109B over niacin receptor GPR109A. IBC 293 is a highly selective agonist for GPR109B, a human orphan G-protein-coupled receptor expressed in adipocytes.
-
3-Hydroxyoctanoic Ac...
3-Hydroxyoctanoic Acid is one of the hydroxy-carboxylic acids (HCAs) that serve as intermediates of energy metabolism. It is an agonist of the orphan receptor GPR109B.
-
Myristyl nicotinate
Myristyl nicotinate is an ester prodrug being developed for delivery of nicotinic acid (NIC) into the skin for prevention of actinic keratosis and its progression to skin cancer.
